2015: The Year in Multiple Sclerosis News

Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.

With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.

Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.

Increasingly, pharmacists are leading the obesity management team.

HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.

A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.

A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.

Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.